> Detailanzeige

Müller, Moritz; Posch, Florian; Kiem, Dominik; Barth, Dominik; Horvath, Lena; Stotz, Michael; Schaberl-Moser, Renate; Pichler, Martin; Greil, Richard; Jost, Philipp J.; Seeber, Andreas; Amann, Arno; Schlick, Konstantin; Gerger, Armin; Riedl, Jakob M.

Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis
  • Beteiligte: Müller, Moritz; Posch, Florian; Kiem, Dominik; Barth, Dominik; Horvath, Lena; Stotz, Michael; Schaberl-Moser, Renate; Pichler, Martin; Greil, Richard; Jost, Philipp J.; Seeber, Andreas; Amann, Arno; Schlick, Konstantin; Gerger, Armin; Riedl, Jakob M.
  • Erschienen: SAGE Publications, 2021
  • Erschienen in: Therapeutic Advances in Medical Oncology
  • Sprache: Englisch
  • DOI: 10.1177/17588359211039930
  • ISSN: 1758-8359
  • Schlagwörter: Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Background:</jats:title><jats:p> The level of evidence for palliative second-line therapy in advanced esophageal squamous cell carcinoma (aESCC) is limited. This is the first study that reports efficacy data comparing second-line therapy + active symptom control (ASC) versus ASC alone in aESCC. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We conducted a tri-center retrospective cohort study ( n = 166) including patients with aESCC who had experienced disease progression on palliative first-line therapy. A propensity score model using inverse probability of treatment weighting (IPTW) was implemented for comparative efficacy analysis of overall survival (OS) in patients with second-line + ASC ( n = 92, 55%) versus ASC alone ( n = 74, 45%). </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> The most frequent second-line regimens used were docetaxel (36%) and paclitaxel (18%). In unadjusted primary endpoint analysis, second-line + ASC was associated with significantly longer OS compared with ASC alone [hazard ratio (HR) = 0.49, 95% confidence interval (CI): 0.35–0.69, p &lt; 0.0001]. However, patients in the second-line + ASC group were characterized by more favorable baseline features including a better Eastern Cooperative Oncology Group (ECOG) performance status, a longer first-line treatment duration and lower C-reactive protein levels. After rigorous adjusting for baseline confounders by re-weighting the data with the IPTW the favorable association between second-line and longer OS weakened but prevailed. The median OS was 6.1 months in the second-line + ASC group and 3.2 months in the ASC group, respectively (IPTW-adjusted HR = 0.40, 95% CI: 0.24–0.69, p = 0.001). Importantly, the benefit of second-line was consistent across several clinical subgroups, including patients with ECOG performance status ⩾1 and age ⩾65 years. The most common grade 3 or 4 adverse events associated with palliative second-line therapy were hematological toxicities. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> This real-world study supports the concept that systemic second-line therapy prolongs survival in patients with aESCC. </jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang